Sanacora, Wilkinson Receive $12.6M in Funding for Ketamine Study
Gerard Sanacora, MD, PhD, George D. and Esther S. Gross Professor of Psychiatry, and Samuel Wilkinson, MD, associate professor of psychiatry, have received $12.6 million in funding from the Patient-Centered Outcomes Research Institute (PCORI) for the study, “Comparative Effectiveness of Racemic Ketamine versus S-Ketamine (Spravato) for Depression.”
Ketamine and the Neurobiology of Depression: Toward Next-generation Rapid-acting Antidepressant Treatments
John Krystal, MD, Robert L. McNeil, Jr. Professor of Translational Research and Professor of Psychiatry, of Neuroscience, and of Psychology; and Irina Esterlis, PhD, associate professor of psychiatry, are first and senior authors, respectively, of a review published in Proceedings of the National Academy of Sciences Perspective that considers what scientists have learned from studies of ketamine and to suggest future directions for the optimization of rapid-acting antidepressant treatment.Source: Proceedings of the National Academy of Sciences Perspective
Ketamine Effectively Treats Depression. Do the Benefits Outweigh the Risks?
Sophie Holmes, PhD, assistant professor of psychiatry, told National Geographic that continued research is needed to determine who might benefit from being treated by ketamine, the drug often prescribed in cases of severe depression and anxiety.Source: National Geographic
The Intricate Interaction Between Expectations and Therapeutic Outcomes of Psychedelic Agents
Sina Nikayin, MD, assistant professor of psychiatry, and Gerard Sanacora, MD, PhD, George D. and Esther S. Gross Professor of Psychiatry, are co-authors of a viewpoint in JAMA Psychiatry that explores how expectations influence outcomes of psychedelic drug therapy.Source: JAMA Psychiatry
Long term Structural and Functional Neural Changes Following a Single Infusion of Ketamine in PTSD
Or Duek, PhD, assistant professor adjunct of psychiatry, and Ilan Harpaz-Rotem, PhD, professor of psychiatry and of psychology, are first and senior authors, respectively of a study published in Neuropsychopharmacology that tests the potential of a single infusion of ketamine, followed by brief exposure therapy, to enhance post-retrieval extinction of post-traumatic stress disorder trauma memories.Source: Neuropsychopharmacology
Sanacora, Holmes Discuss Ketamine's Impact on Depression on Podcast
Gerard Sanacora, MD, PhD, George D. and Esther S. Gross Professor of Psychiatry, and Sophie Holmes, PhD, assistant professor of psychiatry, Gerard Sanacora, MD, PhD, George D. and Esther S. Gross Professor of Psychiatry, and Sophie Holmes, PhD, assistant professor of psychiatry, spoke about depression and mental health in Parkinson’s disease, as well as how ketamine can treat depression, on the Trembling EMT Podcast.Source: Trembling EMT Podcast
Time for a National Ketamine Registry, Experts Say
Gerard Sanacora, MD, PhD, George D. and Esther S. Gross Professor of Psychiatry, spoke to Medscape about the effort to create a ketamine registry to collect data on dosage, treatment frequency, adverse events, and long-term outcomes in patients receiving the therapy for depression and other mental health conditions.Source: Medscape
Four Yale Researchers Honored at the 2022 Association for Clinical and Translational Science Awards
The collaboration that advanced the discovery of ketamine as a treatment for depression was among four Yale award winners at the Association for Clinical and Translational Science (ACTS) annual meeting held in Chicago from April 20 through 22.
Wilkinson Honored with New Investigator Award from ISCTM
Samuel Wilkinson, MD, Assistant Professor of Psychiatry and Assistant Director of the Yale Depression Research Program, has been awarded a New Investigator Award from the International Society of CNS Clinical Trials and Methodology (ISCTM).
Sanacora featured in CBS This Morning report on ketamine as a treatment for depression
Gerard Sanacora, MD, PhD, Professor of Psychiatry and Director of the Yale Depression Research Program, was interviewed for a CBS This Morning report on the use of ketamine to treat depression.Source: CBS This Morning
Ketamine for severe depression: 'How do you not offer this drug to people?'
NPR's news program All Things Considered spoke to Gerard Sanacora, MD, PhD, Professor of Psychiatry and Director of the Yale Depression Research Program about the use of the drug ketamine to treat depression.Source: NPR's "All Things Considered"
Yale Psychiatry ketamine research highlighted in The Washington Post
Gerard Sanacora, MD, PhD, professor of psychiatry and director of the Yale Depression Research Program, is featured in a Washington Post report on the impact the drug ketamine has on people who suffer from depression.Source: The Washington Post
Depression treatments inspired by ketamine move ahead in tests
Antidepressant drugs that work in hours instead of weeks could be on the market within three years, researchers say. "I think it's highly probable that we'll see some version of one of these treatments being approved in the relatively near future," says Dr. Gerard Sanacora, director of the Yale Depression Research Program.Source: NPR
Suicide prevention and ketamine
Suicide, a significant public health problem, is closely linked with mental health conditions, especially depression. At the Yale Depression Research Clinic, a clinical trial is now underway to determine whether esketamine, a form of the drug ketamine, can help prevent suicide in depressed patients.